Edwards Lifesciences price target raised to $95 from $90 at Stifel

Stifel raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $90 and keeps a Buy rating on the shares. The TAVR performance in Q2 is “the best since 2023 and an encouraging indicator that the EARLY TAVR data is positively impacting physician utilization,” the analyst tells investors in a post-earnings note. Recent physician conversations and wider-ranging due diligence have “repeatedly pointed to EARLY TAVR providing a positive halo effect” on Edwards’ TAVR growth, the analyst added.